A Phase III victory for Synergy Pharmaceuticals' ($SGYP) constipation drug has made the company an attractive takeout target, analysts say, with the acquisitive Valeant Pharmaceuticals ($VRX) a potential suitor. As Cantor's Irina Rivkind Koffler wrote in a research note, plecanatide's success in treating chronic idiopathic constipation sets the stage for a likely FDA approval, and Valeant, already at work in the gastrointestinal space, may see a lucrative opportunity to compete with the likes of Ironwood Pharmaceuticals ($IRWD) and Allergan ($AGN). More